Status:
UNKNOWN
Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research
Lead Sponsor:
Peking University First Hospital
Collaborating Sponsors:
Ministry of Science and Technology of the People´s Republic of China
Southern Medical University, China
Conditions:
Primary Hypertension
Eligibility:
All Genders
45+ years
Brief Summary
The purpose of this study is to determine whether the effectiveness of levamlodipine maleate (xuanning) is noninferior to amlodipine besylate (Norvasc) in treatment of hypertension in a Chinese primar...
Detailed Description
It is a multicenter, prospective cohort study with large sample size. It is to evaluate the effect on the incidence of cardiovascular and cerebrovascular endpoint events and blood pressure control in ...
Eligibility Criteria
Inclusion
- systolic pressure ≥140mmHg or diastolic pressure ≥90mmHg or receiving antihypertensive drug treatment
- Patient himself/herself or his/her family member has already signed the informed consent form
- Patient is fit for use of Levamlodipine Maleate or amlodipine besylate
- Age≥45
Exclusion
- patient with secondary hypertension
- patients who has suffered from myocardial infarction or stroke within the latest 3 months
- patients who has obvious intelligence、hearing and limb's activity disability
- Patients with severe disease, with a life expectancy of less than two years
Key Trial Info
Start Date :
February 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT01844570
Start Date
February 1 2013
End Date
December 1 2015
Last Update
May 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, China, 100034